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SUMMARY 
Background:  The association between preoperative blood glucose (BG) concentration and 
outcomes after noncardiac surgery and the impact of the diabetes diagnosis status remain 
unclear. We tested two hypotheses: that preoperative BG is related to surgical outcomes; and that 
this relationship depends on the diabetes diagnosis status of the patient. 
Methods:  We retrospectively analysed data on 61,536 consecutive elective noncardiac surgery 
patients treated at our tertiary care facility. logistic regression models were used to test the 
hypotheses before and after adjustment for baseline patient characteristics. Our primary outcome 
was a composite of in-hospital serious complications and mortality. A second primary outcome 
was one-year mortality. 
Results:  The crude incidence of the composite in-hospital outcome was significantly related to 
preoperative BG (P<0.001), but not after covariable adjustment (P = 0.40). This relationship did 
not significantly differ between patients with and without diagnosed diabetes (P = 0.09).  
One-year mortality was significantly related to preoperative BG, both univariably (P<0.001) and 
after covariable-adjustment (P<0.001). Patients with diagnosed diabetes and preoperative  
euglycaemia generally had worse one-year mortality than  patients without diabetes and the same 
BG (e.g., OR [95% CI] of 1.27 [1.06, 1.53] at 6 mmol litre-1 [108 mg dl -1],  P=0.003). 
Conversely, hyperglycaemic patients with diagnosed diabetes displayed a significantly lower 
one-year mortality than hyperglycaemic patients without diabetes (OR [95% CI] of 0.58 [0.44, 
0.77] at 12 mmol litre-1 [216 mg dl -1], P<0.001). 
Conclusions:  For elective noncardiac surgery, preoperative hyperglycaemia should be given 
greater consideration in patients without diabetes than in patients with diagnosed diabetes. 
. 
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Current data offer no guidance on whether an elective procedure should be cancelled in 
light of a given level of hyperglycaemia. Lack of guidance stems in part from the fact that the 
association between preoperative blood glucose concentration and postoperative complications 
after noncardiac surgery is not very clear.  In noncardiac surgery patients, preoperative blood 
glucose levels above 11.1 mmol litre-1 (200 mg dl-1) have been shown to be associated with a 
2.1-fold higher risk in overall 30-day mortality and a 4-fold higher risk of 30-day cardiovascular 
mortality.1 Hyperglycaemia was associated with a 4-fold increased risk of pulmonary embolism 
(PE) in a small study of patients undergoing total joint replacement.2 However, these studies 
were limited; for they evaluated only particular outcomes (PE and 30-day mortality) in specific 
noncardiac surgery subpopulations. Moreover, no data are available on the association between 
preoperative hyperglycaemia and serious postoperative complications as well as one-year 
mortality in a large cohort of patients undergoing different noncardiac surgical procedures.  
In the intensive care unit (ICU) setting, the effect of blood glucose concentrations on 
outcomes appears to be dependent on diabetic status. Hyperglycaemia upon admission to the 
ICU has been shown to be an independent risk factor for in-hospital mortality only in patients 
without diabetes.3 Hyperglycaemia during the ICU stay was associated with significantly 
increased ICU mortality in patients without, compared to those with diabetes mellitus suggesting 
that hyperglycaemia may bear different clinical and biological implications in patients depending 
on their chronic metabolic status.4 Furthermore, a meta-analysis of two randomised trials showed 
reduced mortality with intensive insulin therapy in ICU patients was evident only in patients 
without a history of diabetes mellitus.5 However, in elective noncardiac surgery, the impact of a 
patient’s diabetes diagnosis status on the association between preoperative glucose 
concentrations and postoperative outcomes and mortality has not been investigated.  
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We tested the hypotheses that in elective noncardiac surgery patients, preoperative blood 
glucose concentration is related to postoperative in-hospital outcomes and to one-year mortality, 
and that this relationship is more pronounced in patients without a diagnosis of diabetes mellitus.  
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METHODS 
Data were extracted with the Cleveland Clinic Institutional Review Board (IRB)’s 
approval of the Anaesthesiology Institute’s Perioperative Health Documentation System (PHDS) 
for quality improvement purposes and for research on patients who present for noncardiac 
surgery. The need for informed consent was waived. Data were aggregated from the electronic 
anaesthesia information system and hospital electronic medical records (EMR). Supplemental 
demographic and clinical data in other institutional databases were imported into the registry 
either manually or through computer interfaces. Data validations were built into the registry to 
ensure the quality of data.  
Selection and description of participants 
The studied population was defined as patients undergoing elective noncardiac surgery at 
our institution between January 2005 and November 2009, and included only the most recent 
operation per patient. (Table 1)  Patients were excluded if data were unavailable for the specified 
type of surgery or preoperative glucose concentration measurement. Patients with American 
Society of Anesthesiologists Physical Status (ASA PS) of > IV were also excluded.  
 
Technical information 
Glucose concentrations were measured by the central laboratory at the time of the pre-
operative evaluation (as a part of a basic or complete metabolic panel) in patients who had 
significant past medical history including diabetes, and/or undergoing surgery of more than low 
risk. Moreover, in patients with a diabetes diagnosis, glucose concentrations were measured 
immediately pre-operatively by the point of care testing using Accu-Chek Inform system (Roche 
Diagnostics, Indianapolis, IN, USA). Each Accu-Check device was checked in three dimensions 
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[linearity, inter-method (lab vs. meter), and meter-meter] and used only when acceptable results 
on all three metrics were found. Additionally, calibrations with low and high controls were 
performed daily to ensure continued high performance. Glucose measurement included in the 
analysis was the last value available before surgery documented in the EMR for a given patient. 
No glucose concentration measurements performed after the induction of anaesthesia for surgery 
was included .  History of diabetes mellitus was screened for as follows: a Health Quest system 
which is an online system of patients’ self-reporting is required to be completed by all surgical 
candidates and validated by a surgical team member. Also a history and physical examination is 
mandated to be completed within 30 days of surgery. Patients were considered diagnosed with 
diabetes if they had a history of either type 1 or type 2 diabetes, and/or receiving insulin or oral 
hypoglycemic medications. 
 
During the time of the study, the target ranges for blood glucose control in the hospital 
were as follows: In the recovery room, <11.1 mmol litre-1  (200mg dl-1)whereas in the ICU, it 
was 3.9-7.2 mmol litre-1 (70-130 mg dl-1) for the first two years, and 4.4-6.7 mmol litre-1 (80-120 
mg dl-1) for the last three years; whereas on the regular nursing wards, it was 3.9-8.3 mmol litre-1 
(70-150 mg dl-1). 
In-hospital morbidity outcomes were identified by ICD-9 codes for postoperative 
complications. In addition, using laboratory measurements, we identified patients with 
postoperative myocardial infarctions (for details, see Table 2, second column). One-year 
mortality was determined through searching hospital EMR and the Social Security Death Index 
(SSDI) through mid-2011. 
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Statistical Analysis 
First, a preliminary analysis was undertaken to study the relationship between 
preoperative blood glucose concentrations and hemoglobin A1c (HbA1c) values, among those 
who had HbA1c measured within 90 days prior to the date of surgery.  For this preliminary 
analysis, we used quantile regression.6 7  Restricted cubic splines were used to model potential 
non-linear relationships. 
To evaluate if preoperative blood glucose concentration was related to the incidence of 
each endpoint, we used logistic regression models. Using a model without covariates, we first 
estimated for a given outcome its crude (unadjusted) incidence as a function of preoperative 
glucose concentration. Natural cubic splines with five degrees of freedom were used to model 
potential nonlinearities in the incidence function (and for any continuous predictors used in the 
logistic regression models described henceforth).  After estimation of the crude incidence 
function, we developed a multivariable model which estimated the incidence function after 
adjusting for potential confounding variables.  These potential confounding variables are listed in 
Table 1.  
Prior to multivariable modelling, a single approximate Bayesian bootstrap7 imputation 
was used to impute missing potential confounder values (because only three patients had a 
history of cerebrovascular or transient ischaemic attack, we combined this variable with history 
of carotid disease for modelling purposes). The null hypothesis of no relationship between 
preoperative glucose and the outcome was evaluated within both the unadjusted and potential 
confounder-adjusted models using Wald chi-squared tests. 
 Since certain surgeries were represented by too few patients to accommodate direct 
adjustment (i.e., small cell sizes), we adjusted for type of surgery as follows: First, we 
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aggregated patients’ primary procedure into one of 244 categories of the U.S. Agency for 
Healthcare Research and Quality Clinical Classifications Software (AHRQ-CCS).8 Next, three 
senior anaesthesiologists (BA, JF, MA) independently rated each of these 244 categories from 0 
to 10 on a scale of surgical risk. The mean of the three raters’ estimates of surgical risk was then 
used for adjustment in our multivariable models. 
For the second hypothesis, regarding the differences between patients with and without a 
history of diabetes mellitus, we also used unadjusted and covariable-adjusted logistic regression 
models. We used the same covariables for adjustment as in the first analysis addressing the 
associations in the total patient population. In these models, relationships between preoperative 
glucose and the incidence of an outcome were estimated separately for patients with and without 
diagnosed diabetes. Odds ratio functions of baseline glucose concentration, comparing patients 
with and without diagnosed diabetes, were also estimated. Using respective Wald chi-squared 
tests, we evaluated the null hypothesis of similar relationships between the two populations 
before and after covariable adjustment. Provided there was evidence of significantly different 
relationships between patients with diabetes diagnosis and those without diabetes, we used a 
generalized Wald test,9, 10 to evaluate whether or not glucose was related to the outcome within 
each respective patient population. 
R statistical software version 2.15.1 (The R Foundation for Statistical Computing, Vienna, 
Austria) was used for all statistical analysis. The Type I error rate for our study was fixed at 0.05 
by controlling the outcome-specific Type I error rate at 0.025; the Bonferroni correction for 
multiple comparisons within an outcome was also implemented, where applicable. 
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RESULTS 
Data from 75,654 ASA PS I-IV patients undergoing elective noncardiac surgery at our 
institution between January 2005 and November 2009 were available. Excluded were patients 
with missing preoperative blood glucose concentration (N = 12,060) as well as patients with 
missing data on type of surgery (N = 1,306) and patients with missing preoperative medications 
data (N = 752). (see flow chart, Figure 1) The resulting sample comprised 61,536 patients. 
Patient and pre-surgical characteristics are summarised in Table 1. The overall median [1st 
quartile, 3rd quartile] serum glucose concentration for the sample was 5.2 [4.7, 6.1] mmol litre-1 
(94 [84, 110] mg dl-1); median glucose for patient with diagnosed of diabetes was 7.0 [5.5, 9.5] 
mmol litre-1 (126 [100, 171] mg dL-1) and 5.1 [4.6, 5.7] mmol litre-1 (92 [83, 103] mg dl-1) for 
patients without diabetes diagnosis. Of the 51,809 patients without  diagnosed diabetes, 1,616 
(3.1%) had a blood glucose value greater than 8 mmol litre-1 (144 mg dl-1) and 390 (0.8%) had a 
blood glucose greater than 11 mmol litre-1(198 mg dl-1).  
There were 3,929 patients who had available HbA1c values measured within 90 days 
prior to their operation.  Quantile regression curves estimating from these cases the 10th 
percentile, first quartile, median, third quartile, and 90th percentile of serum glucose as a function 
of hemoglobin A1c are shown in Appendix 1. 
Individual outcomes comprising the composite in-hospital outcome were uniformly 
represented (incidences of 1-3%) except for mortality (0.5%) and wound disruption (0.5%) 
(Table 2). Overall, the crude incidence (Bonferroni-adjusted 95% CI) was 9.91% (9.65%, 
10.19%). The crude incidence was significantly related to preoperative blood glucose 
concentration (P<0.001, Figure 2a), ranging from approximately 8-11% for patients with glucose 
concentration of 4-6 mmol litre-1(72-108 mg dl-1), to approximately 12-16% for those with 
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glucose concentration above 7 mmol litre-1(126 mg dl-1). However, the incidence was not 
significantly related to preoperative blood glucose concentration after adjustment for covariables 
(P=0.40, Figure 2b). 
The crude incidence (Bonferroni-adjusted 95% CI) of one-year mortality was 5.41% 
(5.24%, 5.60%). This crude incidence was significantly related to preoperative blood glucose 
concentration, reaching a minimum of 3.5% at a concentration of 4.7 mmol litre-1 (85 mg dl-1) 
and increasing to >9% for preoperative blood glucose levels above 10 mmol litre-1 (180 mg dl-1) 
(Figure 2c). After covariable adjustment, a statistically significant relationship remained 
(P<0.001, Figure 2d). 
There were 9,727 patients (15.8%) who were previously diagnosed as having diabetes 
mellitus. The crude incidence of the composite in-hospital outcome for patients with diabetes 
was approximately 15% regardless of preoperative blood glucose level, whereas for patients 
without diabetes, the incidence ranged from 7-9% for patients with glucose concentration of 3.3-
5.5 mmol litre-1 (60-100 mg dl-1) to 13-15% for patients whose preoperative blood glucose 
concentration was above 8 mmol litre-1 (144 mg dl-1) (Figure 3a). However, after adjustment for 
covariables, we found that the relationship between preoperative blood glucose and the 
probability of postoperative complication did not significantly differ between patients with and 
without diabetes mellitus (P=0.09; Figure 3b). 
The crude incidence of one-year mortality was estimated to be approximately 8-11% 
across the range of preoperative blood glucose concentrations for patients with diabetes, except 
for those with concentrations 3.3-5.0 mmol litre-1(60-90 mg dl-1), where the incidence was 
approximately 10-14% (Figure 3c). The crude incidence for patients without diabetes was 
strongly related to preoperative blood glucose, ranging from 3% to 5% for patients with glucose 
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concentrations of 3.3-5.5 mmol litre-1 (60-100 mg dl-1) to >12% for patients with preoperative 
blood glucose above 12 mmol litre-1(216mg dl-1). After adjusting for covariables, significantly 
different relationships between patients with and without diabetes mellitus remained (P<0.001; 
Figure 3d). The generalized Wald test p-values were P = 0.33 for the patients with diagnosed 
diabetes and P<0.001 for the patients without, indicating no significant relationship between 
glucose concentration and one-year mortality for patients with diagnosed diabetes but a strong 
relationship among patients without that diagnosis. 
Adjusted odds ratio curves comparing patients with and without diabetes mellitus on both 
primary endpoints are shown in Figure 4 and summarised numerically in Appendix 2. The 
adjusted odds ratio for the composite outcome was generally not significantly different from 1.0 
over the range of preoperative blood glucose concentrations. On the other hand, the adjusted 
odds ratio for one-year mortality was significantly and nonlinearly related to preoperative blood 
glucose. Based on the point wise confidence bounds in Figure 4, patients with diagnosed diabetes 
and with preoperative blood glucose of 3.6-4.9 mmol litre-1 (65-88 mg dl-1) had significantly 
increased odds of mortality compared with patients without diabetes diagnosis. This odds ratio 
declined as preoperative blood glucose increased. Patients with diabetes and preoperative blood 
glucose >8.5 mmol litre-1 (153 mg dl-1) had significantly lower odds of mortality than patients 
without diabetes. 
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DISCUSSION  
We evaluated the statistical relationship between preoperative blood glucose concentration and 
postoperative in-hospital outcomes as well as one-year mortality, and the impact of a diagnosis 
of diabetes mellitus on these relationships, in a very large cohort of patients undergoing elective 
noncardiac surgery. In our cohort, preoperative hyperglycaemia was directly related to poor 
postoperative in-hospital outcomes, as well as one-year mortality in the univariable model for all 
patients. In the multivariable model, the independent association between hyperglycaemia and 
one-year mortality, but not in-hospital composite outcome, remained significant. A preoperative 
diagnosis of diabetes mellitus significantly altered these associations. For a given level of 
hyperglycaemia, patients with diabetes mellitus had a lower risk of 1-year mortality, whereas for 
low to normal preoperative blood glucose concentrations, patients with diabetes mellitus 
diagnosis had a higher risk of death compared to patients without diabetes. 
 In other words, the relationship between glucose and 1-year mortality was weak (a flat curve) if 
patients were already diagnosed with diabetes. Conversely, if patients did not have diabetes 
diagnosis, there was a clear increasing rate of 1-year mortality once glucose concentration 
increased. That is not to say that diabetic status is not important. If one compared patients 
without diabetes and normal glucose concentrations (i.e. true negatives) against those with 
diagnosed diabetes with normal glucose concentrations – so a situation where missed diabetes 
diagnosis would not be an issue – mortality is higher among patients with diagnosed diabetes .” 
Our results on in-hospital outcomes appear at variance with results from prior studies 
performed on noncardiac surgery patients. Preoperative hyperglycaemia (>11.1 mmol litre-1[200 
mg dl-1]) was associated with a 4-fold increased risk of pulmonary embolism in a small study of 
patients undergoing total major joint replacement.2 In noncardiac, nonvascular surgery patients, 
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preoperative blood glucose levels greater than 11.1 mmol L-1 (200 mg dl-1) have been associated 
with a 2.1-fold increased risk in overall 30-day mortality.1  
An intriguing finding of our current study is that preoperative blood glucose was 
independently related to long-term outcomes (one-year mortality) and not to poor short-term  
in-hospital outcomes. A possible explanation for this finding is that preoperative hyperglycaemia 
reflects a chronic risk for death independent of the surgery. Another explanation may lie in the 
pro-inflammatory effect of hyperglycaemia, which could affect one-year mortality, especially 
given that HbA1c % generally increased with increasing blood glucose concentrations—
indicating a chronic process. Blood glucose concentration has been shown to be independently 
related to C-reactive protein (CRP) levels (a marker of inflammation) in healthy subjects. CRP 
levels increased continuously across the spectrum of fasting blood glucose concentrations, even 
within the normal range.11 However, the impact of such a pro-inflammatory response may not be 
clinically evident immediately. Milazzo and colleagues identified preoperative elevated 
concentrations of CRP as a predictor of recurrent ischaemia up to six years postoperatively.12 
In our study, patients with diagnosed diabetes mellitus and preoperative blood glucose 
>8.5 mmol litre-1 (153 mg dl-1) had significantly lower odds of mortality than patients without 
diabetes diagnosis who had similar preoperative blood glucose concentrations. On the other 
hand, patients with diagnosed diabetes mellitus and preoperative blood glucose within 3.6-4.9 
mmol litre-1 (65-88 mg dl-1) had a higher one-year mortality compared not only to patients 
without diabetes diagnosis with similar levels, but also to patients with diagnosed diabetes and 
higher preoperative blood glucose levels.  
Patients without diabetes diagnosis who are hyperglycaemic, probably have diabetes 
albeit undiagnosed  and thus untreated. Early diagnosis and treatment of diabetes may lessen its 
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burden and delay its associated complications.13-14   In an earlier study we showed that 21% of 
noncardiac surgery patients without a diagnosis of diabetes are hyperglycaemic and more than 
half of those have undiagnosed diabetes.15 Similar findings have been also reported by 
Hatzakorzian and colleagues.16 While previously fasting glucose concentrations were used to 
diagnose diabetes,17 more recently, HbA1c has been advocated to be used as a screening test to 
diagnose diabetes18-19 
A confounding factor, however, is that clinicians may have been more inclined to 
monitor and eventually to treat abnormal perioperative blood glucose levels in patients with a 
diagnosis of diabetes, but not those without that diagnosis. This differential management is in 
part explained by clinicians’ belief that sensitivity to IV insulin varies depending on prior 
treatment with insulin.20 In addition, anaesthesiologists are concerned about hypoglycaemia 
because symptoms are masked by general anaesthesia and sedation.21 Hence, clinicians are more 
reluctant to treat hyperglycaemia in patients without diabetes diagnosis; because aggressive 
insulin protocols in cardiac surgery and in critical care patients have been shown to evoke 
considerably high rates of hypoglycaemia.22-25. Such a different treatment strategy in patients 
with and without diabetes diagnosis may have introduced a bias in our observations. 
Furthermore, patients with preoperative hyperglycaemia who are not diagnosed with diabetes 
likely had no access to quality general medical care (or poor compliance with maintaining 
following up with accessible general medical care). One can certainly make the argument that 
the higher the degree of preoperative glucose concentration, the worse the degree of poor 
medical care. Needless to say, poor medical care would be expected to be major determinant of 
subsequent outcomes.  
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And finally, in patients with established type 2 diabetes, glycaemic thresholds for 
counter-regulatory hormone secretion can be altered. Symptoms of hypoglycaemia and the onset 
of counter-regulatory hormone release can occur at normal glucose values.26-27  
Findings similar to ours were reported by Whitcomb and colleagues,3 who studied the 
impact of hyperglycaemia diagnosed upon ICU admission on outcomes. They concluded that 
hyperglycaemia upon ICU admission was an independent risk factor for in-hospital mortality 
only in patients without diabetes mellitus.  
Although our analysis considered only preoperative glucose concentrations without 
adjusting for the effects of in-hospital glucose management for these patients, somewhat similar 
trends were observed in patients who had undergone glucose control strategies in the ICU. Van 
den Berghe and colleagues, reporting on the cumulative results of two large ICU randomised 
trials of intensive insulin therapy, concluded that such an intervention reduced mortality in all 
patients except those with an established diagnosis of diabetes mellitus.5 Similarly, when 
Krinsley and colleagues evaluated 5,365 consecutive ICU patients, they found that mean glucose 
concentrations within the hyperglycaemic range were associated with higher mortality in patients 
without diabetes.28 However, in their cohort, strict euglycaemia in patients diagnosed with 
diabetes was associated with a survival benefit in a multivariable model.  
Likewise, Egi and colleagues observed increased mortality with increasing mean blood 
glucose concentrations in ICU patients without diabetes mellitus compared to patients with 
diabetes mellitus.4 Graham and colleagues 29 showed that in the ICU, survivors with diagnosed 
diabetes had higher maximum glucose concentrations than did non-survivors without a 
diagnosed diabetes. Also, in their cohort the unadjusted mortality rates were significantly higher 
for patients with diabetes than for those without diabetes for a maximum glucose below 7.2 
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mmol litre-1(129 mg dl-1), but the opposite was the case for a maximal blood glucose level of 9.0 
mmol litre-1(162 mg dl-1).  
Cumulatively the data may suggest that expected benefits, if any, of tight glucose control 
may be determined by the pre-morbid diabetes diagnosis status.24 30-31 More research is needed to 
improve our understanding of the complex association between blood glucose and outcome in 
noncardiac surgery patients, and randomised controlled studies are required 32-33. For such 
studies, our data may help to define optimal blood glucose target levels for patients with and 
without diabetes. It should be highlighted as mentioned above that some investigations of tight 
glucose control in the ICU reported a higher risk of hypoglycemia.24 31 34-35 Current 
recommendations thus favour more moderate targets in the range of 7.8-10.0 mmol litre-1(140-
180 mg dl -1).34 36 
Our study had some limitations. First, this was a retrospective review of a hospital 
database. As such, there remains the potential of unavailable data confounding the relationships 
of interest. Specifically, data on intra-operative and postoperative glucose management were 
unavailable. Accurate study of the relationships of interest while taking into account intra-
operative and postoperative glucose management was impossible because this information was 
available for only a limited number of patients and such information is difficult to obtain in 
retrospect. Such analysis would require a large prospective clinical study. Second, we excluded 
patients for whom a preoperative blood glucose determination was unavailable, which may have 
introduced selection bias. Third, the generalisability of our results is limited by the fact that our 
cohort is from a single institution, and appears to be composed of patients at higher risk than 
average. (Indeed, approximately half of our patients were ASA PS ≥3).  Moreover, our hospital 
had certain targets for in hospital glycemic management that may have influenced the results.   
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Finally, determination of in-hospital outcomes for our study relied on a search of discharge 
diagnosis ICD-9-CM codes. Although these codes are susceptible to under-reporting, we 
nevertheless believe that the discharge diagnosis codes are highly sensitive in determining which 
patients experience major in-hospital events. Moreover, there is no reason to believe that 
possible under-reporting could be associated with diabetes diagnosis status or with ascertainable 
preoperative glucose levels, to the extent that it would introduce bias in our estimates. Finally, 
the second primary outcome, one-year mortality, is a robust endpoint which is not affected by 
possible bias in the use of the ICD-9-CM codes.  
 In summary, in elective noncardiac surgery for a relatively high risk patient population, 
one-year mortality – but not the studied composite in-hospital morbidity endpoint – was 
independently associated with differences in preoperative blood glucose concentration. Patients 
without diabetes diagnosis and with preoperative hyperglycaemia showed higher one-year 
mortality than patients with diabetes with the same level of preoperative hyperglycaemia. 
Patients with diagnosed diabetes and preoperative glucose concentrations in the lower 
euglycaemic range had a higher one-year mortality than patients without diabetes with the same 
levels of preoperative euglycaemia.  
Thus, clinicians should consider checking preoperative glucose concentration and screen 
for hyperglycaemia in patients without the diagnosis of diabetes as it is the case in those with 
diabetes diagnosis. On making the decision whether to proceed with or delay elective noncardiac 
surgery, hyperglycaemia should be considered more so in patients without a diabetes diagnosis 
compared to those with diabetes.  Further research is required to confirm above findings and 
determine whether a specific perioperative glucose management strategy can improve outcomes 
following noncardiac surgery in patients with and without diabetes mellitus. 
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Table 1: Summary of demographic, morphometric, and preoperative patient characteristics. 
Results presented as mean ± standard deviation, median [first and third quartiles], or percentages 
as appropriate 
% Missing Factor   All Patients 
Patients 
without 
diabetes 
diagnosis 
Patients with 
Diabetes 
diagnosis 
   (N=61,536) (N = 51,809) (N = 9,727) 
      
 Blood Glucose (mg/dl) 94 [84, 110] 92 [83, 103] 126 [100, 171] 
 Age (years) 57.3 ± 15.5 56.3 ± 15.8 63.0 ± 12.9 
 Male Gender 47.3% 46.5 51.7 
1.6 Race Caucasian 84.4% 85.6 77.9 
  African American 11.9% 10.7 18.0 
  Other 3.7%   3.7   4.1 
 Year of Surgery 2007.1 ± 1.3 2007.1 ± 1.3 2007.1 ± 1.3 
7.9 Body Mass Index (kg/m2) 28 [24, 33] 27 [24, 32] 31 [27, 37] 
0.2 
ASA Physical 
Status I 4.2%   5.0   0.1 
  II 43.5% 48.3 18.0 
  III 46.8% 42.5 69.9 
  IV 5.4%   4.2 11.9 
 Cancer  29.3% 29.1 30.3 
 Hypertension 49.0% 43.3 79.6 
 Coronary Artery Disease 13.2% 10.6 27.2 
 History of CABG 4.9%   3.8 10.8 
 History of PCI 5.2%   4.3 10.0 
 Myocardial Infarction 5.5%   4.4 11.0 
 Congestive Heart Failure 4.3%   3.1 10.7 
 Ventricular Arrhythmia 1.3%   1.1   2.1 
 Cerebrovascular Attack/TIA 0.0%   0.0   0.0 
 Carotid Disease 0.1%   0.1   0.2 
 Liver Disease 2.4%   1.7   5.9 
 COPD 10.1%   9.5 13.3 
56.7 Smoker 28.3% 29.6 21.1 
 Deep Vein Thrombosis 1.4%   1.2   2.2 
1.5 Serum Hematocrit (%) 40.8 ± 4.8 41.1 ± 4.6 39.3 ± 5.3 
 
Serum Creatinine >176.8 micromol litre -1( > 2mg 
dl-1) 3.7%   2.9   7.9 
  Surgical Risk Score# 4.1 ± 1.6 4.1 ± 1.7 4.2 ± 1.6 
ASA= American Society of Anesthesiologists, CABG = Coronary artery bypass graft, COPD = Chronic obstructive 
pulmonary disease, PCI = Percutaneous Coronary Intervention, TIA = Transischemic attack
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Table 2: Summary of complications comprising the in-hospital composite outcome.  
Complication Description           N (%) 
In-Hospital Mortality    298 (0.48) 
Neurological Complications Nervous system complications, anoxic brain 
damage, cerebral  hypoxia, stroke 
  387 (0.63) 
Cardiac Complications Cardiac arrest, cardiac insufficiency, 
cardiorespiratory failure, heart failure, myocardial 
infarction (postoperative CKMB ≥ 4.0% and CK ≥ 
220 U/L or postoperative cardiac TnT ≥ 0.1 ng/ml) 
1,492 (2.42) 
Pulmonary & Respiratory 
Complications 
Pneumothorax, pulmonary embolism/infarction, 
adult respiratory distress syndrome, pulmonary 
edema, acute respiratory insufficiency, shock lung, 
tracheostomy complications, transfusion-related 
acute lung injury 
1,737 (2.82) 
Infectious Complications Ventilator-associated pneumonia, Mendelson's 
syndrome, pneumonia/aspiration, sepsis, septicemia, 
other postoperative infections 
1,362 (2.21) 
Urinary Complications Urinary tract stoma, internal anastomosis and 
bypass of urinary tract, oliguria/anuria, acute renal 
failure/insufficiency, acute tubular necrosis. 
  748 (1.22) 
Hemorrhagic Complications Hemorrhage, hematoma, seroma 1,626 (2.64) 
Wound Disruption Dehiscence of operation wound, disruption of suture 
materials or other closure method, rupture of 
operation wound 
  325 (0.53) 
   
COMPOSITE OUTCOME One or more of the above complications 6,100 (9.91) 
CKMB = creatine kinase myocardial band; TnT = cardiac troponin T
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Figure legends 
Figure 1: Study flow chart. ASA = American Society of Anesthesiologists 
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Figure 2: Crude and covariable-adjusted incidence of composite in-hospital 
morbidity/mortality and one-year all-cause mortality.  
Estimates given as pointwise 95% confidence bands (confidence bands adjusted for 
simultaneous comparisons using the Bonferroni method). P-values from Wald tests 
assessing the relationship between baseline glucose and each outcome (statistical 
significance after the Bonferroni correction for simultaneous inference on two outcomes 
given by asterisks).  Covariable-adjusted estimates are adjusted for all factors shown in 
Table 1. To convert to mg dl-1, multiply the mmol litre-1 value by 
18.
1.  
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Figure 3: Crude and covariable-adjusted incidence of composite in-hospital 
morbidity/mortality and one-year all-cause mortality, by baseline diabetic status.  
Estimates given as pointwise 95% confidence bands (confidence bands adjusted for 
simultaneous comparisons using the Bonferroni method). P-values from Wald tests of 
equal relationships between baseline glucose and the respective outcome among the 
patients with and without a diagnosed diabetes (statistical significance after the 
Bonferroni correction for simultaneous inference on two outcomes given by asterisks). 
Covariable-adjusted estimates are adjusted for all factors shown in Table 1. To convert to 
mg dl-1, multiply the mmol litre-1 value by 18. 
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Figure 4: Covariable-adjusted odds ratio for composite in-hospital morbidity/mortality and 
one-year mortality as a function of preoperative serum glucose concentration.  
Shaded regions represent pointwise 95% confidence intervals, adjusted for simultaneous 
inference on two outcomes. Odds ratios represent patients with diabetes diagnosis (DM) 
vs. those without diabetes diagnosis (Non-DM) . Estimates are adjusted for all factors 
shown in Table 1. To convert to mg dl-1, multiply the mmol litre-1 value by 18. 
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Appendices: 
Appendix 1: Serum glucose as a function of haemoglobin A1c.  
Displayed are estimates of the 10th percentile, first quartile, median, third quartile, and 
90th percentile of serum glucose as a function of haemoglobin A1c.  These curves thus 
summarize the distribution of serum glucose at each abscissa of haemoglobin A1c.  
Estimates obtained from respective quantile regression models and are estimated using 
restricted cubic splines with 5 degrees of freedom to allow for potential nonlinearities in 
the relationship. 
To convert to mg dl-1, multiply the mmol litre-1 value by 18 
 
Appendix 2: Odds ratio estimates comparing patient with and without diabetes diagnosisfor 
composite in-hospital morbidity/mortality and for one-year mortality, as well as 
Wald test p-values testing the null hypothesis of odds ratio equal to 1.  Odds ratios 
correspond to those given in Figure 4.  P-values corresponding to statistically 
significant odds ratios after the Bonferroni correction are in italics. 
   
